Nuclear Radiology: Page 70

GE launches MIND Coalition
By AuntMinnieEurope.com staff writers
GE Healthcare has unveiled its new Making an Impact on Neurodegenerative Diseases (MIND) initiative to help physicians improve the worldwide detection, diagnosis, and management of neurological conditions such as Alzheimer's and Parkinson's disease.
July 14, 2011
France invests in nuclear medicine
By AuntMinnieEurope.com staff writers
French President Nicolas Sarkozy has confirmed plans to invest 1 billion euros in future nuclear programs, including a fourth-generation reactor research, according to a report in World Nuclear News.
June 29, 2011
Lantheus launches phase III flurpiridaz F-18 trial
By AuntMinnieEurope.com staff writers
Lantheus Medical Imaging has launched the first of two phase III clinical trials of a PET radiopharmaceutical for use in detecting coronary artery disease.
June 29, 2011
Aspect Imaging partners with Cage
By AuntMinnieEurope.com staff writers
Aspect Imaging has signed an agreement with Cage Chemicals to develop and manufacture Aspect's PhenoQuant line of contrast agents for preclinical research.
June 28, 2011
Germany allocates funds for Mo-99 production
By AuntMinnieEurope.com staff writers
The German Federal Ministry of Health has awarded more than 1 million euros ($1.4 million U.S.) in R&D funding for producing the radioisotope molybdenum-99 (Mo-99) at the research neutron source Forschungs-Neutronenquelle Heinz Maier-Leibnitz (FRM II).
June 27, 2011
Philips inks nuclear medicine deal with Russia
By AuntMinnieEurope.com staff writers
Philips Healthcare parent Royal Philips Electronics and Rosatom, the Russian State Atomic Energy Corporation, have signed a nuclear medicine research and manufacturing deal.
June 19, 2011
IBA, Wilex meet FDA on Redectane trial
By AuntMinnieEurope.com staff writers
Radiopharmaceutical developer Ion Beam Applications (IBA) and drug company Wilex recently met with the U.S. Food and Drug Administration to discuss the regulatory review process for IBA's Redectane PET/CT radiopharmaceutical.
June 19, 2011
Don't write off nuclear cardiology, urges U.K. specialist
By Edna Astbury-Ward, PhD
The stunning success of cardiac CT perfusion has led some experts to question whether nuclear cardiology has a future, but it may be premature to write off nuclear cardiology. It is a robust, tried, and tested field supported by very established data, according to a U.K. specialist.
June 7, 2011
2011 06 08 08 40 52 250 2011 06 08 Nuclear Thumb
SNM: Hybrid PET/MRI study among top 5 research papers
By Wayne Forrest
SAN ANTONIO - The first-ever study on the clinical use of PET/MRI and a breakthrough on the use of FDG-PET to detect fevers of unknown origin were among the top research papers outlined Monday at this week's Society of Nuclear Medicine (SNM) annual meeting.
June 7, 2011
2011 06 07 09 54 33 43 Fever Unknown Origin Thumb
GE signs PET agent R&D deal with ImaginAb
By AuntMinnieEurope.com staff writers
GE Healthcare has signed an R&D deal with ImaginAb to develop new PET radiopharmaceuticals based on ImaginAb's antibody fragment technology.
June 6, 2011
PET scanner shows early breast cancer
By AuntMinnieEurope.com staff writers
European researchers say they have developed a clinical PET system with enhanced resolution and the sensitivity to detect breast cancer in its early stages.
May 19, 2011
PET enables better monitoring of intratumoral changes
By Becky McCall
Growing use of hypofractionation in clinical practice and its link to increased treatment resistance due to tumor cell hypoxia means that it may be beneficial to visualize and quantify hypoxic areas with PET imaging to monitor changes in tumor metabolism during treatment.
May 18, 2011
2011 05 19 11 21 20 441 Bussink Thumb
Previous Page
Page 70 of 90
Next Page